Zivo Bioscience, Inc. · OTC:ZIVO

Zivo Bioscience — Investor Presentation (August 2024)

15 slides from Zivo Bioscience's investor presentation, August 2024

  1. Slide 1: Transformative Opportunities in Therapeutics & Nutrition

    (OTCQB: ZIVO) Transformative Opportunities in Therapeutics & Nutrition Updated: August 2024

  2. Slide 2: Disclaimer

    Disclaimer SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Some of the statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These sta

  3. Slide 3: Investment Overview

    Investment Overview One Natural Source. Numerous Commercial Opportunities. Developing novel therapeutics and functional food ingredients to power immune health Currently Generating Revenue • Direct-to-consumer launch of Zivolife , a nutritional supplement for the human green powder and vegan protein

  4. Slide 4: Development History

    Development History • Cultivation techniques One common natural technology, improved • Commercial scale ZivolifeTM product begins commercial direct-to- two value creating paths 2022 – 2024: Commercial cultivation development manufacturing in place consumer sales via www.zivo.life. begins in late 202

  5. Slide 5: ZIVO Bioscience At-a-Glance

    ZIVO Bioscience At-a-Glance Nutrition Therapeutics • Growth and distribution of ZivolifeTM, ZIVO’s • Identification and development of extracts, fractions or proprietary whole algal biomass, for use as molecules derived from proprietary algal polyculture a food or food ingredient to leverage its uni

  6. Slide 6: Nutrition: Zivolife – Proprietary Algal Biomass

    Nutrition: Zivolife – Proprietary Algal Biomass Our first revenue-generating, commercially-available product $1.0 billion market by 2031 Global green powder market Background  Zivolife is natural, non-GMO, and a source of plant-based protein, naturally occurring beta glucan and fiber  Sustainable,

  7. Slide 7: Nutrition: Committed Revenue Stream Grows with Scale

    Nutrition: Committed Revenue Stream Grows with Scale 24,000 kg annual purchase commitment1 ZWorldwide is ZIVO’s global distribution partner, Algae production pond with an initial focus on North America scaling plans  Commits to minimum annual volume purchases for 5 years  ZWorldwide to purchase en

  8. Slide 8: Nutrition: Additional Nutrition Opportunities

    Nutrition: Additional Nutrition Opportunities ZIVO will develop algae based products to address other food, supplement, and cosmetic markets Food or Supplement Ingredient Green Powder Health Foods Snack Foods Other Foods Cosmetics Geographic Expansion Dry Healthy versions of tortilla Baby food Topic

  9. Slide 9: Nutrition: Significant Market Opportunity

    Nutrition: Significant Market Opportunity Proprietary dried algal biomass as a food or food ingredient Nutritive compounds found in ZIVO algae include functional food ingredients proven to enhance overall health in humans Market Opportunity Cultivation Model $6.3 billion in 2021  Presently growing

  10. Slide 10: Therapeutic: Significant Market Opportunity

    Therapeutic: Significant Market Opportunity Bioproducts from Zivo proprietary assets feature broad therapeutic potential in animals and humans. Initial Commercial Application Market Overview  Coccidiosis treatment designed to be introduced in poultry feed or drinking water - IP protected via global

  11. Slide 11: Therapeutic: Validated Efficacy in Numerous Poultry Studies

    Therapeutic: Validated Efficacy in Numerous Poultry Studies More than 20 independent research trials to evaluate the efficacy of ZIVO’s bioactive compounds in the treatment of coccidiosis have been completed Validated efficacy and mechanism-of-action studies in poultry gut health Intestinal Damage 

  12. Slide 12: Therapeutic: Additional Opportunities

    Therapeutic: Additional Opportunities ZIVO will expand products/technology into other therapeutic opportunities, and employ a business model to license proprietary molecules or bioproducts to monetize its intellectual property portfolio Poultry Other (Livestock) Porcine (Livestock) Bovine (Livestock

  13. Slide 13: Where ZIVO is Headed?

    Where ZIVO is Headed? Nutrition Therapeutic Algal Biomass Molecules Extracts Compounds Dry Mixes Complexes Strategic Partnerships & Regional Distributors Poultry Digestive Health  Establish regional distributorships  Prospective licensing or joint development deal  Find partners to create new mar

  14. Slide 14: Leadership Team

    Leadership Team John B. Payne – President and CEO Harlan L. Miller III, PhD – VP Technology and Global Supply Served on ZIVO’s Board since 2013 and Chairman since 2019. He Dr. Miller is a recognized expert in algal production systems, has a significant management experience in publicly-traded previo

  15. Slide 15: Investment Overview

    Investment Overview One Natural Source. Numerous Commercial Opportunities. Developing novel therapeutics and functional food ingredients to power immune health Currently Generating Revenue • DTC launch in June 2023 of Zivolife , a nutritional supplement for the human green powder and vegan protein m

ZIVO Bioscience — Investor Presentation (August 2024) on 6ix